2012
Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?
Patel MI, Rhoads KF, Ma Y, Ford JM, Visser BC, Kunz PL, Fisher GA, Chang DT, Koong A, Norton JA, Poultsides GA. Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement? Annals Of Surgical Oncology 2012, 20: 1631-1638. PMID: 23149854, DOI: 10.1245/s10434-012-2724-5.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdolescentAdultAgedAged, 80 and overCaliforniaChemotherapy, AdjuvantFemaleGastrectomyHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedNeoplasm StagingProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesStomach NeoplasmsTreatment OutcomeYoung AdultConceptsAJCC/UICC staging systemUICC staging systemStaging systemStage IBLymph nodesGastric adenocarcinomaAJCC/UICC stageAJCC/UICC systemCurative-intent surgical resectionSeventh editionKaplan-Meier methodOverall survival probabilityStatewide Health PlanningCancer registry dataNew grouping systemAdjuvant chemotherapyAdjuvant radiotherapySurgical resectionMedian ageUICC stageAsian patientsDischarge abstractsMedian numberRegistry dataGastric cancer
2009
Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
de Bruin M, Kunz P, Sharma V, Norton J, Bastidas J, Chang D, Koong A, Koong A, Balise R, Ford J, Fisher G. Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. Journal Of Clinical Oncology 2009, 27: e15674-e15674. DOI: 10.1200/jco.2009.27.15_suppl.e15674.Peer-Reviewed Original ResearchStanford Cancer CenterGEJ cancerAdjuvant chemoradiotherapyRetrospective reviewCycles of carboplatinPercentage of patientsGastroesophageal junction cancerGastroesophageal junction adenocarcinomaStandard of careExternal beam radiotherapyInfusional 5FUModified regimenPo bidPositive gastricResectable gastricAdjuvant treatmentCurative intentCurative resectionGastrointestinal toxicityMean followStage IBStage IIIAStage IIIBJunction cancerOverall survival